Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Acute Bacterial Skin And Skin Structure Infections Market Value Expansion And Long-Term Growth Outlook

The global market for diagnosing and treating acute bacterial skin and skin structure infections has experienced robust expansion recently. Projections indicate a rise from $12.9 billion in 2025 to $14.09 billion by 2026, demonstrating a compound annual growth rate of 9.2%. Factors contributing to this historical growth trajectory include a scarcity of readily available broad-spectrum antibiotics, an increasing incidence of infections acquired in healthcare settings, heightened public and medical awareness regarding the potential complications of skin infections, expanded access to healthcare within communities, and the widespread implementation of standardized infection control procedures.

The global market for acute bacterial skin and skin structure infections is poised for substantial expansion, projected to reach $20.79 billion by 2030, reflecting a compound annual growth rate of 10.2%. This anticipated surge is fueled by advancements in novel antibiotic development, increased funding for antimicrobial research, the proliferation of community-focused infection control initiatives, broader access through hospital pharmacy networks, and the integration of swift diagnostic tools. Key influencing factors during this period will include a rise in the occurrence of these infections, greater acceptance of innovative antibiotics and combination treatments, the growth of both hospital and community healthcare infrastructure, a higher utilization of both oral and injectable antibiotic treatments, and concerted efforts to curb rates of infections acquired within healthcare settings.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13282&type=smp

Acute Bacterial Skin And Skin Structure Infections Market Development Factors: Which Trends Are Supporting Demand?

The increasing incidence of skin ailments is anticipated to be a significant driver for the expansion of the acute bacterial skin and skin structure infections market in the coming period. Skin infections, characterized by the invasion and proliferation of microorganisms like bacteria, fungi, or viruses within the skin, result in a spectrum of symptoms and distress. This surge in skin infections subsequently boosts the demand for effective therapeutic interventions, including antibiotics and novel treatment modalities, to manage acute bacterial and skin structure infections, thereby facilitating optimal patient care and recovery. For example, data released in March 2023 by the World Health Organization, a UN agency headquartered in Switzerland, indicated that approximately 1.8 billion individuals worldwide contend with skin conditions at any given time. Among these, neglected tropical diseases account for roughly 10%, with fungal and bacterial infections comprising 34% and 23% respectively, frequently contributing to substantial mortality. Consequently, the escalating occurrence of skin infections is poised to fuel the growth trajectory of the acute bacterial skin and skin structure infections market.

Acute Bacterial Skin And Skin Structure Infections Market Segment Analysis: What Are The Major Market Categories?

The acute bacterial skin and skin structure infections market covered in this report is segmented –

1) By Type Of Infection: Hospital-Acquired Acute Bacterial Skin And Skin Structure Infections, Community-Acquired Acute Bacterial Skin And Skin Structure Infections

2) By Active Ingredients: Delafloxacin, Vancomycin, Ceftaroline Fosamil, Oritavancin, Tedizolid, Daptomycin, Tigecycline, Linezolid, Other Active Ingredients

3) By Route Of Administration: Oral, Parenteral

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Hospital-Acquired Acute Bacterial Skin And Skin Structure Infections (HABSSSIs): Surgical Site Infections, Catheter-Related Infections, Infections Related To Medical Devices

2) By Community-Acquired Acute Bacterial Skin And Skin Structure Infections (CABSSSIs): Cellulitis, Abscesses, Impetigo, Folliculitis, Wound Infections

Acute Bacterial Skin And Skin Structure Infections Market Transformation Trends: Which Innovations Are Driving Change?

Key players in the acute bacterial skin and skin structure infections market are prioritizing the creation of novel single-administration treatments, like Dalbonova, to enhance their market standing. Dalbonova represents a potent 1500 mg single-dose treatment solution, offering both convenience and efficacy, thus enabling patient recovery with a solitary administration. Demonstrating this trend, BDR Pharmaceuticals International Pvt. Ltd., an Indian firm specializing in active pharmaceutical ingredients and formulations across various therapeutic areas, including acute bacterial skin and skin structure infections, introduced the Dalbonova injection in August 2023. This groundbreaking single-dose therapy targets acute bacterial skin and skin structure infections by minimizing the risk of hospital-acquired conditions and negating the necessity for inpatient care. Specifically formulated for infections caused by certain gram-positive bacteria, Dalbonova Injection is suitable for treating acute bacterial skin and skin structure infections (ABSSSI) in patients across all age groups, from newborns to adults.

Acute Bacterial Skin And Skin Structure Infections Market Leading Companies Driving Competitive Growth

Major companies operating in the acute bacterial skin and skin structure infections market are Pfizer Inc., AbbVie Inc., Novartis AG, GSK PLC, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Lupin Limited, Zydus Lifesciences Limited, Aurobindo Pharma Limited, Glenmark Pharmaceuticals Ltd., Alkem Laboratories Limited, Aspen Pharmacare Holdings Limited, Melinta Therapeutics LLC, Abbott Laboratories, Fresenius SE & Co. KGaA, Menarini Group

Access The Complete Acute Bacterial Skin And Skin Structure Infections Market Report:

https://www.thebusinessresearchcompany.com/report/acute-bacterial-skin-and-skin-structure-infections-global-market-report

Acute Bacterial Skin And Skin Structure Infections Market Global Footprint: Which Region Holds Market Leadership?

Asia-Pacificwas the largest region in the acute bacterial skin and skin structure infections market in 2025. North Americais expected to be the fastest-growing region in the forecast period. The regions covered in the acute bacterial skin and skin structure infections market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model